Swedencare (SECARE.ST) Stock Analysis & AI Equity Report

Drug Manufacturers - Specialty & Generic SEK Explore free reports

Swedencare (SECARE.ST) overview

Swedencare (SECARE.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Swedencare reported revenue of SEK 2,695m and operating profit of SEK 142m; the year-end share price was 38.40 SEK and market capitalisation was SEK 6,129m. Swedencare is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Swedencare's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 6,665mFY 2025
Share price38.40 SEKFY 2025 year end
RevenueSEK 2,695mFY 2025
Operating profitSEK 142mFY 2025
Net earningsSEK 55.5mFY 2025
Market capitalisationSEK 6,129mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Swedencare

Swedencare AB (publ) develops, produces, and sells premium pet health products for dogs, cats, and horses. Its portfolio includes dental care, supplements, topicals, treats, and veterinary-formulated products under brands such as ProDen PlaqueOff®, NaturVet®, Innovet, Pet MD®, Rx Vitamins®, and others. The company sells through veterinarians, pet stores, and online channels across international markets.

Generate the Swedencare report

Swedencare is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Swedencare and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.